Presentation of preclinical data indicating the potential of regRNA-targeting to increase protein levels in a clinically meaningful way, highlighting the company's innovative approach to gene ...
Foghorn Therapeutics Inc. announced advancements in their clinical and preclinical programs, focusing on FHD-909 (LY4050784), a selective SMARCA2 inhibitor currently in a Phase 1 trial targeting ...
A novel drilling plate simulating the tactile and structural properties of natural human dental tissues may provide dental students with increasingly realistic training opportunities in the ...
Vasa Therapeutics ("Vasa"), a clinical stage biotechnology company developing novel therapies for cardiovascular and metabolic aging, announced today that Noreen R. Henig, MD, Chief Medical Officer, ...
MENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new data for ...
SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today ...
A pneumococcal vaccine candidate was one of three infectious disease prospects that GSK removed from phase 2. (solarseven/iStock/Getty Images Plus) GSK has stopped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results